First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

Publication Name: Breast Cancer Res Treat

Author(s): Takayuki Iwamoto, Ju-Seog Lee. Giampaolo Bianchini, Rebekah E. Hubbard

The aims of this study were to compare the performance of six different genomic prognostic markers to predict long-term survival and chemotherapy response on the same patient cohort and assess if clinicopathological variables carry independent prognostic and predictive values. We … Continued

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Publication Name: Breast Cancer Research and Treatment

Author(s): Michael Knauer, Stella Mook, Emiel J. T. Rutgers, Richard A. Bender, Michael Hauptmann, Marc J. van de Vijver, Rutger H. T. Koornstra, Jolien M. Bueno-de-Mesquita, Sabine C. Linn, Laura J. van ’t Veer

Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled … Continued

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Publication Name: The Breast

Author(s): Kathy S Albain, Soonmyung Paik, Laura van ’t Veer

Background: Multigene assays performed on the primary tumors from women with non- metastatic breast cancer provide useful prognostic information and discriminate excellent versus poor outcome potential in diverse clinical scenarios. Recently, analyses were conducted to determine if these assays predict … Continued